Results 231 to 240 of about 215,664 (299)

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Ferroptosis and chemotherapy resistance in ovarian cancer: molecular mechanisms and therapeutic opportunities. [PDF]

J Ovarian Res
Li S, Yang L, Zhu Z.
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Do you want to live forever? Lessons learned from the biology of aging. [PDF]

PLoS Biol
Mair WB, Alvarez-Garcia I.
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Evaluation of the use of dienogest in women with deep endometriosis and ovarian endometrioma: a retrospective cohort study. [PDF]

Rev Assoc Med Bras (1992)
Onishi A, Leonardo-Pinto JP, Benetti-Pinto CL, Yela DA.   +3 more
europepmc   +1 more source

Hereditary and familial breast and ovarian cancer: spectrum of related tumors

, 2008
Pensabene, Matilde
core  

Ovarian Fibrosis Through Comparative Analysis of Collagen Architecture. [PDF]

Mol Reprod Dev
Aitken CJ, Kadhim L, Murray A, Landry DA.   +3 more
europepmc   +1 more source

Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors. [PDF]

Mol Clin Oncol
Zhang L, Xiao L, Wang J, Wang H.
europepmc   +1 more source